Table 1: Patients' characteristics and treatment procedures.
| Patient | Age | Tumor side | Tumor histological characteristics |
Years from initial treatment |
Surgery | Radiotherapy (timing, dose and technique) |
Chemotherapy | Follow-up |
| 1 | 70 | Right | G3 Tm (max Ø 2,7 cm) - R0 | 9 | RM | Immediate RT 50 Gy/20 fr IMRT |
Epi-Ifo (4 cycles) |
NED Alive |
| 2 | 72 | Right | G2 T 3,1 cm - R0 | 6 | RM | Immediate RT 35 Gy/7 fr IMRT |
None | NED Alive |
| 3 | 79 | Left | G2 Tm (max Ø 1,5 cm) - R0 | 5 | RM | Immediate RT 40 Gy/20 fr IMRT |
None | Lung/Bone mets Alive |
| 4 | 59 | Left | G2 T 1,6 cm - R0 | 9 | RM | No RT | Pac (12 cycles) | SD Alive |
| 5 | 68 | Right | G3 Tm (max Ø 1,8 cm) - R0 | 11 | RM | Delayed RT 50 Gy/25 fr IMRT |
Epi (6 cycles) | Lung mets Died |
| 6 | 75 | Left | G3 T 2,6 cm - R0 | 6 | RM | Immediate RT 40 Gy/20 fr IMRT |
None | Lung mets Died |
RM: Radical Mastectomy, Epi: Epirubicin (dose 100 mg/mq day 1), Ifo: Ifosfamide (dose 2 g/mq day 1-3), Pac: Paclitaxel (dose 100 mg/mq weekly), RT: Radiotherapy, IMRT: Intensity-modulated Radiotherapy, fr: Fractions, G: Grading, T: Tumor dimension, Tm: Multiple tumor nodules, R: Status of margins, NED: Non-Evidence of Disease, mets: Distant metastases; SD: Stable Disease.